Orvosi Hetilap
Volume/Issue:
Volume 154: Issue 34
Anxiogenic and depressogenic side-effects of non-psychiatric drugs
Authors: Eszter Kirilly 1 , Xénia Gonda, Gabriella Juhász, and György Bagdy
View More View Less
  • 1 Semmelweis Egyetem, Gyógyszerésztudományi Kar Gyógyszerhatástani Intézet Budapest Nagyvárad tér 4. 1089
  • 2 Semmelweis Egyetem, Általános Orvostudományi Kar Kútvölgyi Klinikai Tömb, Klinikai és Kutatási Mentálhigiénés Osztály Budapest
  • 3 Magyar Tudományos Akadémia–Semmelweis Egyetem Neuropszichofarmakológiai és Neurokémiai Kutatócsoport Budapest
DOI:
https://doi.org/10.1556/oh.2013.29681
Page Count:
1327–1336
Publication Date:
01 Aug 2013
Online Publication Date:
17 Aug 2013
Article Category:
Research Article
Open access

Annak ellenére, hogy számos szomatikus betegség kezelésére alkalmazott – például daganatellenes, antimikrobás, immunmoduláns, neurológiai, illetve hormonháztartásra ható – gyógyszer hathat negatív irányban a hangulatra, ezt egészen a rimonabant 2008-ban emiatt történt visszavonásáig nem kezelték jelentőségének megfelelően. A szerzők a teljes gyógyszerpalettát áttekintve tárgyalják a szorongást és a depressziót, mint gyógyszer-mellékhatásokat. A gyógyszerválasztásnál minden esetben figyelembe kell venni, ha a betegeknél magas a depresszió kialakulásának a kockázata, például, ha már korábban előfordult vagy jelenleg is fennáll a depressziós epizód vagy betegség, ha a családi anamnézisben előfordul depresszió, illetve ha a betegnél olyan neurotikus személyiségvonások állnak fenn, amelyek következtében sérülékenyebb a depressziót kiváltó hatásokkal szemben. A veszélyt jelentő gyógyszerek felírása előtt emellett célszerű figyelembe venni az alkalmazni kívánt szer hatékonyságát, a rendelkezésre álló alternatív gyógyszeres és nem gyógyszeres terápiás lehetőségeket, és minden esetben biztosítani kell a beteg monitorozását a kezelés során az esetleges depressziós vagy szorongásos tünetek mihamarabbi észlelése érdekében. Orv. Hetil., 2013, 154, 1327–1336.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Celano, C. M., Freudenreich, O., Fernandez-Robles, C., et al.: Depressogenic effects of medications: a review. Dialogues Clin. Neurosci., 2011, 13, 109–125.

    Fernandez-Robles C. , 'Depressogenic effects of medications: a review ' (2011 ) 13 Dialogues Clin. Neurosci. : 109 -125.

    • Search Google Scholar

  • Global burden of disease. http://www.who.int/healthinfo/global_burden_disease

  • Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., et al.: Global burden of depressive disorders in the year 2000. Br. J. Psychiatry, 2004, 184, 386–392.

    Chatterji S. , 'Global burden of depressive disorders in the year 2000 ' (2004 ) 184 Br. J. Psychiatry : 386 -392.

    • Search Google Scholar

  • Kotlyar, M., Dysken, M., Adson, D. E.: Update on drug-induced depression in the elderly. Am. J. Geriatr. Pharmacother., 2005, 3, 288–300.

    Adson D. E. , 'Update on drug-induced depression in the elderly ' (2005 ) 3 Am. J. Geriatr. Pharmacother. : 288 -300.

    • Search Google Scholar

  • Fialova, D., Topinkova, E., Gambassi, G., et al.: Potentially inappropriate medication use among elderly home care patients in Europe. JAMA, 2005, 293, 1348–1358.

    Gambassi G. , 'Potentially inappropriate medication use among elderly home care patients in Europe ' (2005 ) 293 JAMA : 1348 -1358.

    • Search Google Scholar

  • Hajjar, E. R., Cafiero, A. C., Hanlon, J. T.: Polypharmacy in elderly patients. Am. J. Geriatr. Pharmacother., 2007, 5, 345–351.

    Hanlon J. T. , 'Polypharmacy in elderly patients ' (2007 ) 5 Am. J. Geriatr. Pharmacother. : 345 -351.

    • Search Google Scholar

  • Kanner, A. M., Nieto, J. C.: Depressive disorders in epilepsy. Neurology, 1999, 53 (Suppl. 2), S26–S32.

    Nieto J. C. , 'Depressive disorders in epilepsy ' (1999 ) 53 Neurology : S26 -S32.

  • Miller, J. M., Kustra, R. P., Vuong, A., et al.: Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs, 2008, 68, 1493–1509.

    Vuong A. , 'Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs ' (2008 ) 68 Drugs : 1493 -1509.

    • Search Google Scholar

  • Mula, M., Sander, J. W.: Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Saf., 2007, 30, 555–567.

    Sander J. W. , 'Negative effects of antiepileptic drugs on mood in patients with epilepsy ' (2007 ) 30 Drug Saf. : 555 -567.

    • Search Google Scholar

  • Lambert, M. V., Robertson, M. M.: Depression in epilepsy: etiology, phenomenology, and treatment. Epilepsia, 1999, 40 (Suppl. 10), S21–S47.

    Robertson M. M. , 'Depression in epilepsy: etiology, phenomenology, and treatment ' (1999 ) 40 Epilepsia : S21 -S47.

    • Search Google Scholar

  • Brent, D. A., Crumrine, P. K., Varma, R., et al.: Phenobarbital treatment and major depressive disorder in children with epilepsy: a naturalistic follow-up. Pediatrics, 1990, 85, 1086–1091.

    Varma R. , 'Phenobarbital treatment and major depressive disorder in children with epilepsy: a naturalistic follow-up ' (1990 ) 85 Pediatrics : 1086 -1091.

    • Search Google Scholar

  • Brent, D. A., Crumrine, P. K., Varma, R. R., et al.: Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics, 1987, 80, 909–917.

    Varma R. R. , 'Phenobarbital treatment and major depressive disorder in children with epilepsy ' (1987 ) 80 Pediatrics : 909 -917.

    • Search Google Scholar

  • Dodrill, C. B.: Behavioral effects of antiepileptic drugs. Adv. Neurol., 1991, 55, 213–224.

    Dodrill C. B. , 'Behavioral effects of antiepileptic drugs ' (1991 ) 55 Adv. Neurol. : 213 -224.

    • Search Google Scholar

  • Levinson, D. F., Devinsky, O.: Psychiatric adverse events during vigabatrin therapy. Neurology, 1999, 53, 1503–1511.

    Devinsky O. , 'Psychiatric adverse events during vigabatrin therapy ' (1999 ) 53 Neurology : 1503 -1511.

    • Search Google Scholar

  • Mula, M., Hesdorffer, D. C., Trimble, M., et al.: The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia, 2009, 50, 1072–1076.

    Trimble M. , 'The role of titration schedule of topiramate for the development of depression in patients with epilepsy ' (2009 ) 50 Epilepsia : 1072 -1076.

    • Search Google Scholar

  • Mula, M., Trimble, M. R., Lhatoo, S. D., et al.: Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia, 2003, 44, 659–663.

    Lhatoo S. D. , 'Topiramate and psychiatric adverse events in patients with epilepsy ' (2003 ) 44 Epilepsia : 659 -663.

    • Search Google Scholar

  • Faught, E., Ayala, R., Montouris, G. G., et al.: Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology, 2001, 57, 1774–1779.

    Montouris G. G. , 'Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures ' (2001 ) 57 Neurology : 1774 -1779.

    • Search Google Scholar

  • Sackellares, J. C., Ramsay, R. E., Wilder, B. J., et al.: Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia, 2004, 45, 610–617.

    Wilder B. J. , 'Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures ' (2004 ) 45 Epilepsia : 610 -617.

    • Search Google Scholar

  • Lemke, M. R.: Depressive symptoms in Parkinson’s disease. Eur. J. Neurol., 2008, 15 (Suppl. 1), 21–25.

    Lemke M. R. , 'Depressive symptoms in Parkinson’s disease ' (2008 ) 15 Eur. J. Neurol. : 21 -25.

    • Search Google Scholar

  • Picillo, M., Rocco, M., Barone, P.: Dopamine receptor agonists and depression in Parkinson’s disease. Parkinsonism Relat. Disord., 2009, 15 (Suppl. 4), S81–S84.

    Barone P. , 'Dopamine receptor agonists and depression in Parkinson’s disease ' (2009 ) 15 Parkinsonism Relat. Disord. : S81 -S84.

    • Search Google Scholar

  • Imamura, K., Okayasu, N., Nagatsu, T.: The relationship between depression and regional cerebral blood flow in Parkinson’s disease and the effect of selegiline treatment. Acta Neurol. Scand., 2011, 124, 28–39.

    Nagatsu T. , 'The relationship between depression and regional cerebral blood flow in Parkinson’s disease and the effect of selegiline treatment ' (2011 ) 124 Acta Neurol. Scand. : 28 -39.

    • Search Google Scholar

  • Flaherty, J. A., Bellur, S. N.: Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population. J. Clin. Psychiatry, 1981, 42, 344–345.

    Bellur S. N. , 'Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population ' (1981 ) 42 J. Clin. Psychiatry : 344 -345.

    • Search Google Scholar

  • Greenberg, R., Meyers, B. S.: Treatment of major depression and Parkinson’s disease with combined phenelzine and amantadine. Am. J. Psychiatry, 1985, 142, 273–274.

    Meyers B. S. , 'Treatment of major depression and Parkinson’s disease with combined phenelzine and amantadine ' (1985 ) 142 Am. J. Psychiatry : 273 -274.

    • Search Google Scholar

  • Bagdy, G., Riba, P., Kecskeméti, V., et al.: Headache-type adverse effects of NO donors: vasodilation and beyond. Br. J. Pharmacol., 2010, 160, 20–35.

    Kecskeméti V. , 'Headache-type adverse effects of NO donors: vasodilation and beyond ' (2010 ) 160 Br. J. Pharmacol. : 20 -35.

    • Search Google Scholar

  • Sørensen, P. S., Larsen, B. H., Rasmussen, M. J., et al.: Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. Headache, 1991, 31, 650–657.

    Rasmussen M. J. , 'Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability ' (1991 ) 31 Headache : 650 -657.

    • Search Google Scholar

  • Mohr, D. C., Goodkin, D. E., Likosky, W., et al.: Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch. Neurol., 1997, 54, 531–533.

    Likosky W. , 'Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis ' (1997 ) 54 Arch. Neurol. : 531 -533.

    • Search Google Scholar

  • Patten, S. B., Metz, L. M., SPECTRIMS Study Group: Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology, 2002, 59, 744–746.

    Metz L. M. , 'Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial ' (2002 ) 59 Neurology : 744 -746.

    • Search Google Scholar

  • Porcel, J., Río, J., Sánchez-Betancourt, A., et al.: Long-term emotional state of multiple sclerosis patients treated with interferon beta. Mult. Scler., 2006, 12, 802–807.

    Sánchez-Betancourt A. , 'Long-term emotional state of multiple sclerosis patients treated with interferon beta ' (2006 ) 12 Mult. Scler. : 802 -807.

    • Search Google Scholar

  • McNeil, G. N., Shaw, P. K., Dock, D. S.: Substitution of atenolol for propranolol in a case of propranolol-related depression. Am. J. Psychiatry, 1982, 139, 1187–1188.

    Dock D. S. , 'Substitution of atenolol for propranolol in a case of propranolol-related depression ' (1982 ) 139 Am. J. Psychiatry : 1187 -1188.

    • Search Google Scholar

  • Oppenheim, G.: Propranolol-induced depression: mechanism and management. Aust. N. Z. J. Psychiatry, 1983, 17, 400–402.

    Oppenheim G. , 'Propranolol-induced depression: mechanism and management ' (1983 ) 17 Aust. N. Z. J. Psychiatry : 400 -402.

    • Search Google Scholar

  • Thiessen, B. Q., Wallace, S. M., Blackburn, J. L., et al.: Increased prescribing of antidepressants subsequent to beta-blocker therapy. Arch. Intern. Med., 1990, 150, 2286–2290.

    Blackburn J. L. , 'Increased prescribing of antidepressants subsequent to beta-blocker therapy ' (1990 ) 150 Arch. Intern. Med. : 2286 -2290.

    • Search Google Scholar

  • Stoudemire, A., Brown, J. T., Harris, R. T., et al.: Propranolol and depression: a reevaluation based on a pilot clinical trial. Psychiatr. Med., 1984, 2, 211–218.

    Harris R. T. , 'Propranolol and depression: a reevaluation based on a pilot clinical trial ' (1984 ) 2 Psychiatr. Med. : 211 -218.

    • Search Google Scholar

  • Pérez-Stable, E. J., Halliday, R., Gardiner, P. S., et al.: The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension. Am. J. Med., 2000, 108, 359–365.

    Gardiner P. S. , 'The effects of propranolol on cognitive function and quality of life: a randomized trial among patients with diastolic hypertension ' (2000 ) 108 Am. J. Med. : 359 -365.

    • Search Google Scholar

  • Ko, D. T., Hebert, P. R., Coffey, C. S., et al.: Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA, 2002, 288, 351–357.

    Coffey C. S. , 'Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction ' (2002 ) 288 JAMA : 351 -357.

    • Search Google Scholar

  • Freis, E. D.: Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N. Engl. J. Med., 1954, 251, 1006–1008.

    Freis E. D. , 'Mental depression in hypertensive patients treated for long periods with large doses of reserpine ' (1954 ) 251 N. Engl. J. Med. : 1006 -1008.

    • Search Google Scholar

  • Keller, S., Frishman, W. H.: Neuropsychiatric effects of cardiovascular drug therapy. Cardiol. Rev., 2003, 11, 73–93.

    Frishman W. H. , 'Neuropsychiatric effects of cardiovascular drug therapy ' (2003 ) 11 Cardiol. Rev. : 73 -93.

    • Search Google Scholar

  • Paykel, E. S., Fleminger, R., Watson, J. P.: Psychiatric side effects of antihypertensive drugs other than reserpine. J. Clin. Psychopharmacol., 1982, 2, 14–39.

    Watson J. P. , 'Psychiatric side effects of antihypertensive drugs other than reserpine ' (1982 ) 2 J. Clin. Psychopharmacol. : 14 -39.

    • Search Google Scholar

  • DeMuth, G. W., Ackerman, S. H.: Alpha-methyldopa and depression: a clinical study and review of the literature. Am. J. Psychiatry, 1983, 140, 534–538.

    Ackerman S. H. , 'Alpha-methyldopa and depression: a clinical study and review of the literature ' (1983 ) 140 Am. J. Psychiatry : 534 -538.

    • Search Google Scholar

  • Long, T. D., Kathol, R. G.: Critical review of data supporting affective disorder caused by nonpsychotropic medication. Ann. Clin. Psychiatry, 1993, 5, 259–270.

    Kathol R. G. , 'Critical review of data supporting affective disorder caused by nonpsychotropic medication ' (1993 ) 5 Ann. Clin. Psychiatry : 259 -270.

    • Search Google Scholar

  • Sternbach, H., State, R.: Antibiotics: neuropsychiatric effects and psychotropic interactions. Harv. Rev. Psychiatry, 1997, 5, 214–226.

    H. State, R. , 'Antibiotics: neuropsychiatric effects and psychotropic interactions ' (1997 ) 5 Harv. Rev. Psychiatry : 214 -226.

    • Search Google Scholar

  • Feinberg, S. S.: Fluoroquinolone-induced depression. Am. J. Psychiatry, 1995, 152, 954–955.

    Feinberg S. S. , 'Fluoroquinolone-induced depression ' (1995 ) 152 Am. J. Psychiatry : 954 -955.

    • Search Google Scholar

  • Gounden, V., van Niekerk, C., Snyman, T., et al.: Presence of the CYP2B6 516G> T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res. Ther., 2010, 7, 32.

    Snyman T. , 'Presence of the CYP2B6 516G> T polymorphism, increased plasma efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients ' (2010 ) 7 AIDS Res. Ther. : 32 -.

    • Search Google Scholar

  • Muñoz-Moreno, J. A., Fumaz, C. R., Ferrer, M. J., et al.: Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev., 2009, 11, 103–109.

    Ferrer M. J. , 'Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review ' (2009 ) 11 AIDS Rev. : 103 -109.

    • Search Google Scholar

  • Lazary, J., Juhasz, G., Hunyady, L., et al.: Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists. Trends Pharmacol. Sci., 2011, 32, 270–280.

    Hunyady L. , 'Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists ' (2011 ) 32 Trends Pharmacol. Sci. : 270 -280.

    • Search Google Scholar

  • Kraus, M. R., Schäfer, A., Schöttker, K., et al.: Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. Gut, 2008, 57, 531–536.

    Schöttker K. , 'Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study ' (2008 ) 57 Gut : 531 -536.

    • Search Google Scholar

  • Schlagenhauf, P., Johnson, R., Schwartz, E., et al.: Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study. J. Travel Med., 2009, 16, 42–45.

    Schwartz E. , 'Evaluation of mood profiles during malaria chemoprophylaxis: a randomized, double-blind, four-arm study ' (2009 ) 16 J. Travel Med. : 42 -45.

    • Search Google Scholar

  • Després, J. P.: Pleiotropic effects of rimonabant: clinical implications. Curr. Pharm. Des., 2009, 15, 553–570.

    Després J. P. , 'Pleiotropic effects of rimonabant: clinical implications ' (2009 ) 15 Curr. Pharm. Des. : 553 -570.

    • Search Google Scholar

  • Van Gaal, L., Pi-Sunyer, X., Després, J. P., et al.: Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care, 2008, 31 (Suppl. 2), S229–S240.

    Després J. P. , 'Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program ' (2008 ) 31 Diabetes Care : S229 -S240.

    • Search Google Scholar

  • FDA: US Food and Drug Administration Advisory Committee. FDA briefing document: Zimulti (rimonabant) tablets, 20 mg. http://www.fda.gov/OHRMS/DOCKETS/AC/07/briefing/2007-4306b1-00-index.htm Accessed Aug 6, 2007

  • Lazary, J., Lazary, A., Gonda, X., et al.: Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2009, 150B, 1118–1127.

    Gonda X. , 'Promoter variants of the cannabinoid receptor 1 gene (CNR1) in interaction with 5-HTTLPR affect the anxious phenotype ' (2009 ) 150B Am. J. Med. Genet. B Neuropsychiatr. Genet. : 1118 -1127.

    • Search Google Scholar

  • Gyombolai, P., Pap, D., Turu, G., et al.: Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action. Mol. Cell. Endocrinol., 2012, 353, 29–36.

    Turu G. , 'Regulation of endocannabinoid release by G proteins: a paracrine mechanism of G protein-coupled receptor action ' (2012 ) 353 Mol. Cell. Endocrinol. : 29 -36.

    • Search Google Scholar

  • Kirilly, E., Gonda, X., Bagdy, G.: CB1 receptor antagonists: new discoveries leading to new perspectives. Acta Physiol. (Oxf.), 2012, 205, 41–60.

    Bagdy G. , 'CB1 receptor antagonists: new discoveries leading to new perspectives ' (2012 ) 205 Acta Physiol. (Oxf.) : 41 -60.

    • Search Google Scholar

  • Kirilly, E., Hunyady, L., Bagdy, G.: Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists. J. Neural Transm., 2013, 120, 177–186.

    Bagdy G. , 'Opposing local effects of endocannabinoids on the activity of noradrenergic neurons and release of noradrenaline: relevance for their role in depression and in the actions of CB(1) receptor antagonists ' (2013 ) 120 J. Neural Transm. : 177 -186.

    • Search Google Scholar

  • Byrne, A., Hnatko, G.: Depression associated with isotretinoin therapy. Can. J. Psychiatry, 1995, 40, 567.

    Hnatko G. , 'Depression associated with isotretinoin therapy ' (1995 ) 40 Can. J. Psychiatry : 567 -.

    • Search Google Scholar

  • Ng, C. H., Schweitzer, I.: The association between depression and isotretinoin use in acne. Aust. N. Z. J. Psychiatry, 2003, 37, 78–84.

    Schweitzer I. , 'The association between depression and isotretinoin use in acne ' (2003 ) 37 Aust. N. Z. J. Psychiatry : 78 -84.

    • Search Google Scholar

  • Hazen, P. G., Carney, J. F., Walker, A. E., et al.: Depression – a side effect of 13-cis-retinoic acid therapy. J. Am. Acad. Dermatol., 1983, 9, 278–279.

    Walker A. E. , 'Depression – a side effect of 13-cis-retinoic acid therapy ' (1983 ) 9 J. Am. Acad. Dermatol. : 278 -279.

    • Search Google Scholar

  • Scheinman, P. L., Peck, G. L., Rubinow, D. R., et al.: Acute depression from isotretinoin. J. Am. Acad. Dermatol., 1990, 22 (6 Pt 1), 1112–1114.

    Rubinow D. R. , 'Acute depression from isotretinoin ' (1990 ) 22 J. Am. Acad. Dermatol. : 1112 -1114.

    • Search Google Scholar

  • Gatti, S., Serri, F.: Acute depression from isotretinoin. J. Am. Acad. Dermatol., 1991, 25 (1 Pt 1), 132.

    Serri F. , 'Acute depression from isotretinoin ' (1991 ) 25 J. Am. Acad. Dermatol. : 132 -.

  • Marqueling, A. L., Zane, L. T.: Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin. Cutan Med. Surg., 2007, 26, 210–220.

    Zane L. T. , 'Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review ' (2007 ) 26 Semin. Cutan Med. Surg. : 210 -220.

    • Search Google Scholar

  • Ng, C. H., Tam, M. M., Celi, E., et al.: Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy. Australas. J. Dermatol., 2002, 43, 262–268.

    Celi E. , 'Prospective study of depressive symptoms and quality of life in acne vulgaris patients treated with isotretinoin compared to antibiotic and topical therapy ' (2002 ) 43 Australas. J. Dermatol. : 262 -268.

    • Search Google Scholar

  • Cohen, M. H., Johnson, J. R., Wang, Y. C., et al.: FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer. Oncologist, 2005, 10, 363–368.

    Wang Y. C. , 'FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer ' (2005 ) 10 Oncologist : 363 -368.

    • Search Google Scholar

  • Rossi, J. F., van Hoof, A., de Boeck, K., et al.: Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J. Clin. Oncol., 2004, 22, 1260–1267.

    Boeck K. , 'Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia ' (2004 ) 22 J. Clin. Oncol. : 1260 -1267.

    • Search Google Scholar

  • DeConti, R. C.: Procarbazine in the management of late Hodgkin’s disease. JAMA, 1971, 215, 927–930.

    DeConti R. C. , 'Procarbazine in the management of late Hodgkin’s disease ' (1971 ) 215 JAMA : 927 -930.

    • Search Google Scholar

  • Haskell, C. M., Canellos, G. P., Leventhal, B. G., et al.: L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N. Engl. J. Med., 1969, 281, 1028–1034.

    Leventhal B. G. , 'L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease ' (1969 ) 281 N. Engl. J. Med. : 1028 -1034.

    • Search Google Scholar

  • Ohnuma, T., Holland, J. F., Freeman, A., et al.: Biochemical and pharmacological studies with asparaginase in man. Cancer Res., 1970, 30, 2297–2305.

    Freeman A. , 'Biochemical and pharmacological studies with asparaginase in man ' (1970 ) 30 Cancer Res. : 2297 -2305.

    • Search Google Scholar

  • Gill, P. S., Wernz, J., Scadden, D. T., et al.: Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J. Clin. Oncol., 1996, 14, 2353–2364.

    Scadden D. T. , 'Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma ' (1996 ) 14 J. Clin. Oncol. : 2353 -2364.

    • Search Google Scholar

  • Cousins, J. P., Harper, G.: Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression. Cancer Lett., 1996, 110, 163–167.

    Harper G. , 'Neurobiochemical changes from Taxol/Neupogen chemotherapy for metastatic breast carcinoma corresponds with suicidal depression ' (1996 ) 110 Cancer Lett. : 163 -167.

    • Search Google Scholar

  • Thornton, L. M., Carson, W. E. 3rd, Shapiro, C. L., et al.: Delayed emotional recovery after taxane-based chemotherapy. Cancer, 2008, 113, 638–647.

    Shapiro C. L. , 'Delayed emotional recovery after taxane-based chemotherapy ' (2008 ) 113 Cancer : 638 -647.

    • Search Google Scholar

  • Bolanos, S. H., Khan, D. A., Hanczyc, M., et al.: Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales. Ann. Allergy Asthma Immunol., 2004, 92, 500–505.

    Hanczyc M. , 'Assessment of mood states in patients receiving long-term corticosteroid therapy and in controls with patient-rated and clinician-rated scales ' (2004 ) 92 Ann. Allergy Asthma Immunol. : 500 -505.

    • Search Google Scholar

  • Henry, N. L., Stearns, V., Flockhart, D. A., et al.: Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. Am. J. Psychiatry, 2008, 165, 1251–1255.

    Flockhart D. A. , 'Drug interactions and pharmacogenomics in the treatment of breast cancer and depression ' (2008 ) 165 Am. J. Psychiatry : 1251 -1255.

    • Search Google Scholar

  • Howell, A., Cuzick, J., Baum, M., et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet, 2005, 365, 60–62.

    Baum M. , 'Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer ' (2005 ) 365 Lancet : 60 -62.

    • Search Google Scholar

  • Pirl, W. F., Greer, J. A., Goode, M., et al.: Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy. Psychooncology, 2008, 17, 148–153.

    Goode M. , 'Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy ' (2008 ) 17 Psychooncology : 148 -153.

    • Search Google Scholar

  • Capuron, L., Ravaud, A., Dantzer, R.: Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J. Clin. Oncol., 2000, 18, 2143–2151.

    Dantzer R. , 'Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy ' (2000 ) 18 J. Clin. Oncol. : 2143 -2151.

    • Search Google Scholar

  • Walker, L. G., Walker, M. B., Heys, S. D., et al.: The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psychooncology, 1997, 6, 290–301.

    Heys S. D. , 'The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial ' (1997 ) 6 Psychooncology : 290 -301.

    • Search Google Scholar

  • O’Brien, S. G., Guilhot, F., Larson, R. A., et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med., 2003, 348, 994–1004.

    Larson R. A. , 'Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia ' (2003 ) 348 N. Engl. J. Med. : 994 -1004.

    • Search Google Scholar

  • Quek, R., Morgan, J. A., George, S., et al.: Small molecule tyrosine kinase inhibitor and depression. J. Clin. Oncol., 2009, 27, 312–313.

    George S. , 'Small molecule tyrosine kinase inhibitor and depression ' (2009 ) 27 J. Clin. Oncol. : 312 -313.

    • Search Google Scholar

  • Wilkins, K. M., Warnock, J. K., Serrano, E.: Depressive symptoms related to infertility and infertility treatments. Psychiatr. Clin. North Am., 2010, 33, 309–321.

    Serrano E. , 'Depressive symptoms related to infertility and infertility treatments ' (2010 ) 33 Psychiatr. Clin. North Am. : 309 -321.

    • Search Google Scholar

  • Warnock, J. K., Bundren, J. C.: Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy. Psychopharmacol. Bull., 1997, 33, 311–316.

    Bundren J. C. , 'Anxiety and mood disorders associated with gonadotropin-releasing hormone agonist therapy ' (1997 ) 33 Psychopharmacol. Bull. : 311 -316.

    • Search Google Scholar

  • Choi, S. H., Shapiro, H., Robinson, G. E., et al.: Psychological side-effects of clomiphene citrate and human menopausal gonadotrophin. J. Psychosom. Obstet. Gynaecol., 2005, 26, 93–100.

    Robinson G. E. , 'Psychological side-effects of clomiphene citrate and human menopausal gonadotrophin ' (2005 ) 26 J. Psychosom. Obstet. Gynaecol. : 93 -100.

    • Search Google Scholar

  • Bagdy, G.: Influence of stress on the development of depression. Lessons about the moderation by genetic variants in the population. [Génjeink és a lelki egészség. A stressz hatásának és a depresszió genomikájának összefüggései és tanulságai.] Magyar Tudomány, 2012, 6, 660–672. [Hungarian]

    Bagdy G. , 'Influence of stress on the development of depression. Lessons about the moderation by genetic variants in the population. [Génjeink és a lelki egészség. A stressz hatásának és a depresszió genomikájának összefüggései és tanulságai.] ' (2012 ) 6 Magyar Tudomány : 660 -672.

    • Search Google Scholar

  • Bagdy, G.: Serotonin, anxiety, and stress hormones. Focus on 5-HT receptor subtypes, species and gender differences. Ann. N. Y. Acad. Sci., 1998, 851, 357–363.

    Bagdy G. , 'Serotonin, anxiety, and stress hormones. Focus on 5-HT receptor subtypes, species and gender differences ' (1998 ) 851 Ann. N. Y. Acad. Sci. : 357 -363.

    • Search Google Scholar
Cover Orvosi Hetilap
Orvosi Hetilap
Print ISSN:
0030-6002
Online ISSN:
1788-6120
Keywords:
depresszió; pszichiátriai mellékhatások; rimonabant; gyógyszermellékhatás; személyre szabott orvoslás; depression; psychiatric side-effects; rimonabant; adverse effects; personalized medicine

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Aug 2020 0 9 8
Sep 2020 0 2 5
Oct 2020 0 4 7
Nov 2020 0 7 6
Dec 2020 0 3 9
Jan 2021 0 5 9
Feb 2021 0 0 0